Loading...
01/11 04:04
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary reflects strong financial performance with 25% revenue growth and improved margins. The guidance is optimistic with expectations of positive adjusted EBITDA in 2025. The Q&A session highlights broad-based growth and strong product adoption, despite management's cautious stance on long-term guidance. No major risks were identified, and the absence of a share repurchase program is a minor negative. Overall, the company's strong growth, margin improvements, and optimistic guidance suggest a positive stock price movement.
Worldwide Revenue $47.3 million, representing approximately 25% growth year-over-year.
U.S. Revenue $44.8 million, reflecting approximately 27% growth year-over-year, driven by a remarkable 27.3% growth in procedure volume.
Gross Profit $37.7 million, an increase of $7.8 million, or 26.2% year-over-year, due to consistent ASP and improved manufacturing and supply chain efficiencies.
Gross Margin Rate 79.7%, an improvement of nearly 80 basis points year-over-year.
Operating Expenses $45.2 million, representing 7.8% growth year-over-year, primarily due to higher commissions related to revenue growth and R&D investments.
Net Loss Narrowed to $6.5 million, or $0.15 per diluted share, compared to a net loss of $10.9 million, or $0.27 per diluted share, showing strong year-over-year progress.
Adjusted EBITDA Positive adjusted EBITDA of approximately $0.5 million compared to an adjusted EBITDA loss of $4 million in the first quarter of 2024.
Cash and Marketable Securities $144.4 million at the end of the quarter.
Cash Usage $5.6 million, a 31.7% improvement over the prior year period.
Revenue Growth (Trailing 12 Months) Approximately $32.6 million.
Adjusted EBITDA Growth (Trailing 12 Months) Improved by approximately $16.8 million.
New Product Launches: In Q1 2026, SI-BONE expects to launch a new SI joint fusion solution that builds on their knowledge of 3D printed titanium implants and application of iFuse INTRA.
Product Expansion: The company introduced iFuse TORQ and iFuse INTRA, expanding their offerings for SI joint dysfunction, which has accelerated procedure volume growth.
New Technology: The second-generation trauma solution, iFuse TORQ TNT, was launched in Q4 2024, targeting sacral insufficiency fractures.
Market Expansion: The total addressable market has increased to over $3.5 billion, with a focus on SI joint dysfunction and pelvic fixation.
Revenue Growth: Worldwide revenue for Q1 2025 reached $47.3 million, a 25% increase, with U.S. revenue at $44.8 million, reflecting a 27% growth.
Operational Efficiency: Gross margin improved to 79.7%, driven by consistent ASP and improved manufacturing efficiencies.
Cash Position: The company exited Q1 2025 with $144.4 million in cash and marketable securities, with a cash usage improvement of 31.7% year-over-year.
Strategic Shift: Transitioning to a hybrid commercial model combining territory managers and third-party agents to enhance market reach.
Focus on Innovation: The company is diversifying its platform with complementary technologies to broaden its physician footprint and revenue streams.
Regulatory Issues: The company mentioned potential impacts of proposed tariffs on their supply chain, although they currently do not anticipate any material impact on gross margins or supply chain due to their domestic manufacturing and secured raw materials.
Economic Factors: Despite macroeconomic uncertainty, the company is not seeing any impact on procedure volumes, attributing this to the essential nature of their services for patients experiencing debilitating pain.
Competitive Pressures: The company is focused on maintaining its leadership position through innovation and expanding its product offerings, which is crucial in a competitive market.
Supply Chain Challenges: While the company sources most raw materials domestically and has secured supply through 2026, they remain vigilant about potential supply chain disruptions.
Market Demand: The company is cautious about potential headwinds in the macroeconomic environment, which could affect demand trends, despite current strong performance.
Revenue Growth: Worldwide revenue for Q1 2025 reached $47.3 million, representing approximately 25% growth.
Procedure Volume Growth: U.S. revenue was $44.8 million, reflecting approximately 27% growth driven by a remarkable 27.3% growth in procedure volume.
Innovation and Product Launches: Expect to launch a new SI joint fusion solution in Q1 2026 and a novel implant targeting spine surgery needs.
Market Expansion: Total addressable market increased to over $3.5 billion with 25% cumulative procedure volume growth.
Physician Engagement: Over 1,400 U.S. physicians performed procedures using SI-BONE products, a 27% increase in physician base.
Commercial Execution: Transitioned to a hybrid sales model, increasing territory productivity by nearly 25%.
Revenue Guidance: Updated full year revenue guidance to range between $193.5 million to $197.5 million, implying 16% to 18% year-over-year growth.
Gross Margin Guidance: Expect full year gross margin to be 78%, up from previous guidance of 77% to 78%.
Operating Expenses Guidance: Fiscal year operating expenses expected to grow approximately 10% at midpoint of revenue guidance.
Adjusted EBITDA Outlook: Continue to expect positive adjusted EBITDA for the full year 2025.
Share Repurchase Program: None
The company raised its guidance midpoint due to strong Q3 performance and expects continued positive momentum in Q4. They achieved positive cash flow from operating activities and have a strong product pipeline with international growth prospects. Gross margins exceeded expectations, and they anticipate further improvement. Despite some vague responses, the overall sentiment from the Q&A is positive, with strong growth drivers and strategic initiatives in place.
The earnings call summary indicates strong financial performance with 25% revenue growth and positive guidance for 2025. The Q&A session highlighted expansion opportunities, strong product adoption, and reimbursement tailwinds, despite some uncertainties in gross margin stabilization. The company's strategic focus on market expansion and new product launches, along with positive adjusted EBITDA expectations, further supports a positive sentiment. These factors, combined with the absence of negative catalysts like margin decline or guidance refusal, suggest a likely stock price increase in the short term.
The earnings call summary reflects strong financial performance with 25% revenue growth and improved margins. The guidance is optimistic with expectations of positive adjusted EBITDA in 2025. The Q&A session highlights broad-based growth and strong product adoption, despite management's cautious stance on long-term guidance. No major risks were identified, and the absence of a share repurchase program is a minor negative. Overall, the company's strong growth, margin improvements, and optimistic guidance suggest a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
